azasetron azasetron azasetron is an antiemetic which acts as a 5-ht3 receptor antagonist, pki = 9.27 it is used in the management of nausea and vomiting induced by cancer chemotherapy (such as cisplatin chemotherapy). azasetron hydrochloride is given in a usual dose of 10 mg once daily by mouth or intravenously. it is approved for marketing in japan, and marketed exclusively by torii pharmaceutical co., ltd. under the trade names "serotone i.v. injection 10 mg" and "serotone tablets 10 mg". pharmacokinetics data from s. tsukagoshi. azasetronclinical dataahfs/drugs.cominternational drug namesroutes ofadministrationoralatc codenonepharmacokinetic databioavailability90%excretion60-70%identifiers iupac name n-(1-azabicyclooctan-8-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide cas number123040-69-7pubchem cid2264iuphar/bps2285chemspider2177 yunii77hc7urr9zkeggd07481 ychemblchembl1598608comptox dashboard (epa)dtxsid7045651 chemical and physical dataformulac17h20cln3o3molar mass349.82 g·mol−13d model (jsmol)interactive image smiles cn1c(=o)coc2c1cc(cl)cc2c(=o)nc3cn4ccc3cc4 inchi inchi=1s/c17h20cln3o3/c1-20-14-7-11(18)6-12(16(14)24-9-15(20)22)17(23)19-13-8-21-4-2-10(13)3-5-21/h6-7,10,13h,2-5,8-9h2,1h3,(h,19,23) ykey:wukzphoxuvcqor-uhfffaoysa-n y (verify) r-azasetron besylate (sens-401) has been studied to prevent hearing loss related to sudden sensorineural hearing loss (ssnhl), acoustic trauma, and cisplatin-induced ototoxicity.